ME Live signaler | Maksimer profitt med Getagraph.com

KJøP 111139 min ago

@ $0.773

Utstedt: 14 feb 2024 @ 21:29

Avkastning: -35.26%

Forrige signal: feb 14 - 16:21

Forrige signal: Selg

Avkastning: 3.62 %

Live Chart Being Loaded With Signals

Commentary (1 mai 2024 @ 22:00):

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics...

Stats
Dagens volum	3.08M
Gjennomsnittsvolum	7.56M
Markedsverdi	241.60M
EPS	$0 ( 2024-02-07 )
Neste inntjeningsdato	( $-0.150 ) 2024-05-26
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.450
ATR14	$0.00100 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-18	Hibbs Kathy L	Buy	38 548	Class A Common Stock
2024-04-18	Hibbs Kathy L	Sell	38 548	Class A Common Stock
2024-04-18	Hibbs Kathy L	Sell	38 548	Stock Option (Right to Buy)
2024-04-04	Hibbs Kathy L	Buy	38 548	Class A Common Stock
2024-04-04	Hibbs Kathy L	Sell	38 548	Class A Common Stock

INSIDER POWER
73.76
Last 100 transactions
Buy: 15 283 999 \| Sell: 2 077 892

Volum Korrelasjon

Lang: -0.06 (neutral)

Kort: -0.98 (very strong negative)

Signal:(35.976) Neutral

23andMe Holding Co. Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

23andMe Holding Co. Korrelasjon - Valuta/Råvare

0.04
( neutral )

-0.68
( moderate negative )

0.00
( neutral )

0.59
( weak )

23andMe Holding Co. Økonomi

Annual	2022
Omsetning:	$299.49M
Bruttogevinst:	$134.50M (44.91 %)
EPS:	$-0.690

FY	2022
Omsetning:	$299.49M
Bruttogevinst:	$134.50M (44.91 %)
EPS:	$-0.690

FY	2022
Omsetning:	$271.89M
Bruttogevinst:	$132.95M (48.90 %)
EPS:	$-0.600

FY	2021
Omsetning:	$243.92M
Bruttogevinst:	$117.01M (47.97 %)
EPS:	$-0.398

Financial Reports:

No articles found.

23andMe Holding Co.

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.